1. CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention
- Author
-
Kayla R. Tunehag, Cameron D. Thomas, Francesco Franchi, Joseph S. Rossi, Ellen C. Keeley, R. David Anderson, Amber L. Beitelshees, Julio D. Duarte, Yan Gong, Richard A. Kerensky, Caitrin W. McDonough, Anh B. Nguyen, Luis Ortega‐Paz, Sanjay Venkatesh, Yehua Wang, Julie A. Johnson, Almut G. Winterstein, George A. Stouffer, Dominick J. Angiolillo, Larisa H. Cavallari, and Craig R. Lee
- Subjects
Black or African American ,clopidogrel ,CYP2C19 ,genetic testing ,percutaneous coronary intervention ,precision medicine ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Cytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary intervention (PCI). However, outcome studies to date have lacked racial diversity. Thus, the impact of CYP2C19 genotype on cardiovascular outcomes in patients treated with clopidogrel who identify as Black or African American remains unclear. Methods and Results Adults among 5 institutions who self‐identified as Black or African American, underwent PCI and clinical CYP2C19 genotyping, and were treated with clopidogrel were included. Data were abstracted from health records. Major atherothrombotic (composite of death, myocardial infarction, ischemic stroke, stent thrombosis, or revascularization for unstable angina) and bleeding event rates within 1 year after PCI were compared across CYP2C19 metabolizer groups using multivariable Cox regression adjusted for potential confounders and baseline variables meeting a threshold of P
- Published
- 2024
- Full Text
- View/download PDF